Literature DB >> 25341459

2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease.

Keith N Fargo1, Paul Aisen2, Marilyn Albert3, Rhoda Au4, Maria M Corrada5, Steven DeKosky6, David Drachman7, Howard Fillit8, Laura Gitlin9, Magali Haas10, Karl Herrup11, Claudia Kawas12, Ara S Khachaturian13, Zaven S Khachaturian14, William Klunk15, David Knopman16, Walter A Kukull17, Bruce Lamb18, Rebecca G Logsdon19, Paul Maruff20, Marsel Mesulam21, William Mobley2, Richard Mohs22, David Morgan23, Ralph A Nixon24, Steven Paul25, Ronald Petersen16, Brenda Plassman26, William Potter27, Eric Reiman28, Barry Reisberg29, Mary Sano30, Rachel Schindler31, Lon S Schneider32, Peter J Snyder33, Reisa A Sperling34, Kristine Yaffe35, Lisa J Bain36, William H Thies1, Maria C Carrillo37.   

Abstract

With increasing numbers of people with Alzheimer's and other dementias across the globe, many countries have developed national plans to deal with the resulting challenges. In the United States, the National Alzheimer's Project Act, signed into law in 2011, required the creation of such a plan with annual updates thereafter. Pursuant to this, the US Department of Health and Human Services (HHS) released the National Plan to Address Alzheimer's Disease in 2012, including an ambitious research goal of preventing and effectively treating Alzheimer's disease by 2025. To guide investments, activities, and the measurement of progress toward achieving this 2025 goal, in its first annual plan update (2013) HHS also incorporated into the plan a set of short, medium and long-term milestones. HHS further committed to updating these milestones on an ongoing basis to account for progress and setbacks, and emerging opportunities and obstacles. To assist HHS as it updates these milestones, the Alzheimer's Association convened a National Plan Milestone Workgroup consisting of scientific experts representing all areas of Alzheimer's and dementia research. The workgroup evaluated each milestone and made recommendations to ensure that they collectively constitute an adequate work plan for reaching the goal of preventing and effectively treating Alzheimer's by 2025. This report presents these Workgroup recommendations.
Copyright © 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Milestones; National Plan to Address Alzheimer's Disease; Policy

Mesh:

Substances:

Year:  2014        PMID: 25341459     DOI: 10.1016/j.jalz.2014.08.103

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  22 in total

1.  Repetitive transcranial magnetic stimulation (rTMS) combined with cognitive training is a safe and effective modality for the treatment of Alzheimer's disease: clinical experience.

Authors:  Jose Martin Rabey; Evgenia Dobronevsky
Journal:  J Neural Transm (Vienna)       Date:  2016-09-08       Impact factor: 3.575

2.  miR-133b is a potential diagnostic biomarker for Alzheimer's disease and has a neuroprotective role.

Authors:  Qin Yang; Qiuling Zhao; Yanliang Yin
Journal:  Exp Ther Med       Date:  2019-08-05       Impact factor: 2.447

3.  Vascular and Metabolic Factors in Alzheimer's Disease and Related Dementias: Introduction.

Authors:  Costantino Iadecola
Journal:  Cell Mol Neurobiol       Date:  2016-02-22       Impact factor: 5.046

4.  Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.

Authors:  Dan Liu; Hui Tang; Xin-Yan Li; Man-Fei Deng; Na Wei; Xiong Wang; Ya-Fan Zhou; Ding-Qi Wang; Peng Fu; Jian-Zhi Wang; Sébastien S Hébert; Jian-Guo Chen; Youming Lu; Ling-Qiang Zhu
Journal:  Mol Ther       Date:  2017-02-13       Impact factor: 11.454

5.  The relative contributions of biomarkers, disease modifying treatment, and dementia severity to Alzheimer's stigma: A vignette-based experiment.

Authors:  Shana D Stites; Jeanine Gill; Emily A Largent; Kristin Harkins; Pamela Sankar; Abba Krieger; Jason Karlawish
Journal:  Soc Sci Med       Date:  2021-12-01       Impact factor: 4.634

6.  Neuronavigated Magnetic Stimulation combined with cognitive training for Alzheimer's patients: an EEG graph study.

Authors:  Fabrizio Vecchio; Davide Quaranta; Francesca Miraglia; Chiara Pappalettera; Riccardo Di Iorio; Federica L'Abbate; Maria Cotelli; Camillo Marra; Paolo Maria Rossini
Journal:  Geroscience       Date:  2021-12-31       Impact factor: 7.713

7.  What features of stigma do the public most commonly attribute to Alzheimer's disease dementia? Results of a survey of the U.S. general public.

Authors:  Shana D Stites; Jonathan D Rubright; Jason Karlawish
Journal:  Alzheimers Dement       Date:  2018-03-27       Impact factor: 21.566

8.  Computerised cognitive training for 12 or more weeks for maintaining cognitive function in cognitively healthy people in late life.

Authors:  Nicola J Gates; Anne Ws Rutjes; Marcello Di Nisio; Salman Karim; Lee-Yee Chong; Evrim March; Gabriel Martínez; Robin Wm Vernooij
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27

9.  Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients.

Authors:  Eric D Vidoni; In-Young Choi; Phil Lee; Gregory Reed; Na Zhang; Joseph Pleen; Jonathan D Mahnken; Jonathan Clutton; Annette Becker; Erica Sherry; Rebecca Bothwell; Heidi Anderson; Robert A Harris; William Brooks; Heather M Wilkins; Lisa Mosconi; Jeffrey M Burns; Russell H Swerdlow
Journal:  Alzheimers Dement       Date:  2020-07-27       Impact factor: 21.566

10.  Precision Repetitive Transcranial Magnetic Stimulation Over the Left Parietal Cortex Improves Memory in Alzheimer's Disease: A Randomized, Double-Blind, Sham-Controlled Study.

Authors:  Yanli Jia; Luoyi Xu; Kehua Yang; Yingchun Zhang; Xinghui Lv; Zhenwei Zhu; Zheli Chen; Yunlong Zhu; Lili Wei; Xia Li; Mincai Qian; Yuedi Shen; Weiming Hu; Wei Chen
Journal:  Front Aging Neurosci       Date:  2021-06-29       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.